Engineered human adaptation to other worlds
Rewriting human biology so that people can live where unmodified humans cannot - tolerating radiation, altered gravity, different atmospheres and food chains without technological shelter.
In shortEngineered human adaptation to other worlds, from Lilith's Brood (Xenogenesis) (Octavia E. Butler, 1989) and Mars Trilogy (Red Mars, Green Mars, Blue Mars) (Kim Stanley Robinson, 1992), is at technology readiness level 3 of 9 (experimental proof of concept) at its weakest link. Held back by Safe heritable embryo genome editing, In vitro gametogenesis, Engineered cellular radiation tolerance and Predictive genotype-to-trait models for complex traits. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $11B–46B.
The Oankali trade genes, reshaping human and construct bodies at will - cancer-derived regeneration, controlled chemistry, tolerance of their ship's environment - and insist humans cannot continue unmodified.
Mars-born generations diverge physically under 0.38 g, and deliberate genetic and physiological adaptation of settlers is argued over throughout the trilogy.
Closest todayTardigrade Dsup protein delivered as mRNA reduced radiation DNA damage locally in mice in 2025; no human has been genetically modified for environmental tolerance, and heritable editing remains preclinical.
Dependency stack
- Adaptation that persists across generations has to be installed in the germline, where mosaicism and structural damage are unsolved
- Mosaicism - edits arrive after the first division, so cells of the same embryo differ
- On-target large deletions, chromosome loss and chromothripsis occur in edited embryos and are invisible to biopsy-based testing
- A biopsy of a few cells cannot certify the genome of the whole future person, so safety cannot be established before a birth
TRL 3- In vitro gametogenesisbottleneckEditing and screening gametes before fertilization avoids embryo mosaicism altogether
- Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
- Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
- Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth
TRL 3 - Any multi-trait germline change needs many simultaneous precise edits
✕3 blockers›
- Structural variants and large deletions accumulate with edit count and are missed by short-read screening
- Edited cell lines lose clonogenic and developmental potency after many rounds of editing
- No method reaches the thousands of edits implied by whole-genome rewriting
TRL 6- Higher-fidelity, smaller editor and recombinase proteins are the route to many simultaneous edits
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- Deep-space and Martian surface exposure is the hardest environmental constraint on unmodified bodies
- Protection demonstrated locally and for hours to days, not body-wide and chronic as deep-space exposure requires
- Dsup reduces strand breaks but does not address the complex lesions and clustered damage that dominate heavy-ion injury
- Constitutive expression of DNA-protective proteins may blunt apoptosis of damaged cells and raise cancer risk
- No dose-response data against galactic-cosmic-ray-like mixed-ion fields
TRL 3- Protection must be expressed in many tissues, which is a delivery problem
✕3 blockers›
- Systemic LNPs partition to liver and spleen; tropism for kidney, bone marrow and solid tumors is weak
- Anti-AAV immunity excludes many patients and blocks redosing
- Payload size caps (about 4.7 kb for AAV) exclude large multi-gene constructs
TRL 6- Receptor-specific capsids and shuttle peptides are the main route to non-liver tropismTRL 6
- Better-than-natural protective proteins would have to be designedTRL 6
- Permanent tolerance means editing repair pathways, not repeat dosing
✕2 blockers›
- Delivery to tissues beyond liver
- Long-term off-target safety
TRL 6
- Bone density, oxygen handling and metabolic traits are polygenic, and current prediction cannot specify which variants to install
- Scores tag correlated variants rather than causal ones, so editing the top-ranked variant need not move the trait
- Non-additive effects, pleiotropy and gene-environment interaction are unmodeled
- Ancestry portability is poor because training cohorts are predominantly European
TRL 3 - Already-living settlers can only be adapted somaticallyTRL 6
- supportingDeep-space radiation protectionBiological tolerance supplements shielding rather than replacing it, and sets how much shielding is still required
✕2 blockers›
- Galactic cosmic ray shielding mass
- Uncertain biological risk models
plausibleTRL 4- Active magnetic shielding
✕2 blockers›
- REBCO tape cost and manufacturing volume
- Quench detection and protection in large coils
TRL 6
Who could unlock it
- Across several requirements:
- Shoukhrat Mitalipov 2
- PreventiveStartupPublic-benefit corporation announced October 2025 with about $30M - the largest known investment in heritable genome editing - to run preclinical safety research and publish even a negative answer
- Lucas HarringtonResearcher, PreventiveFounder; did his PhD in Jennifer Doudna's lab and co-founded Mammoth Biosciences, and has committed publicly not to advance to clinical use if safety cannot be established
- Shoukhrat MitalipovResearcher, Center for Embryonic Cell and Gene Therapy, Oregon Health & Science UniversityRan the first US human embryo-editing experiments (2017) and the nuclear-transfer oocyte work reported in 2025; consults for embryo-editing startups
- Paula AmatoResearcher, Oregon Health & Science UniversityReproductive endocrinologist on the US embryo-editing team and the one established scientist who agreed to advise Preventive (2025)
- Conception BiosciencesStartupReported the first stem-cell-derived human primary oocytes inside entirely iPSC-derived follicle structures, from a blood draw (June 2026)
- Katsuhiko HayashiResearcher, Osaka UniversityProduced healthy fertile mouse pups from iPSC-derived eggs (2016), the only complete mammalian IVG demonstration, and collaborates with Conception
- Mitinori SaitouResearcher, ASHBi, Kyoto UniversityGenerated human oogonia from iPSCs (Science, 2018) and reconstituted human germline epigenetic reprogramming in vitro (Nature, 2024), defining the steps the field has to reproduce
- GametoStartupIts iPSC-derived ovarian support cell product Fertilo produced the first live birth from stem-cell-assisted egg maturation (December 2024) and is in Phase 3 after a $44M Series C in August 2025
- Giovanni TraversoResearcher, Massachusetts Institute of TechnologyCo-led the polymer-lipid nanoparticle Dsup mRNA work that protected mouse oral and rectal tissue during radiotherapy (Nature Biomedical Engineering, 2025)
- James ByrneResearcher, University of IowaRadiation oncologist who co-led the same 2025 study and is pushing Dsup delivery toward protecting healthy tissue in patients
- NASA Space Radiation LaboratoryGovernment labBrookhaven beamline with the galactic-cosmic-ray simulator that switches ion species and energies rapidly, the only place mixed-field dose-response data can be generated
- NASA Human Research ProgramProgramFunds the space radiation risk work, including carcinogenesis endpoints, that any engineered tolerance claim would have to clear
- Shai CarmiResearcher, Hebrew University of JerusalemQuantified the small expected gain from polygenic embryo selection for height and IQ (2019) and the selection-strategy dependence of disease-risk reduction (eLife, 2021)
- Genomic PredictionCompanyIntroduced the first clinical polygenic embryo test in 2019 and still supplies the LifeView disease-risk product used by IVF clinics
- Orchid HealthStartupPalo Alto company selling whole-genome embryo reports restricted to health risks rather than cognitive or cosmetic traits as of 2026
- HerasightStartupBegan selling embryo predictions for height, BMI, longevity and IQ in 2025, the furthest any vendor has gone beyond disease risk
- Intellia TherapeuticsCompanyIts Phase 3 HAELO trial of lonvo-z (NTLA-2002) in hereditary angioedema met the primary and all key secondary endpoints in April 2026, the first Phase 3 data for any in vivo gene-editing therapy
- David LiuResearcher, Broad Institute of MIT and HarvardInvented base and prime editing; his lab designed the base editor used for baby KJ in 2025 and is extending prime editing to disease-agnostic suppressor-tRNA approaches
- Kiran MusunuruResearcher, University of Pennsylvania and Children's Hospital of PhiladelphiaLed the first patient-specific in vivo base-editing therapy, an LNP-delivered editor given to an infant with CPS1 deficiency (NEJM, May 2025), and is building umbrella platforms for urea-cycle disorders and PKU
- NIH Somatic Cell Genome Editing ConsortiumProgramNIH Common Fund program funding targeted delivery technologies, safety assays and platform clinical-trial pathways; it underwrote the preclinical work behind the KJ therapy
Beyond engineering
- Descendants cannot consent to a heritable adaptation that may be maladaptive on Earth
- Deliberate biological divergence raises questions of political and legal status for adapted populations
- No jurisdiction authorizes heritable human modification for non-medical purposes